Peca Labs Inc. recently raised $587,465 of venture funding from undisclosed investors, PitchBook reports. The Pittsburgh company, which spun out of Carnegie Mellon University and has raised $5.69 million through five rounds, is developing synthetic cardiovascular devices intended to improve the treatment of cardiac defects.

The company’s devices consist of a valved shunt that can be used for the treatment of hypoplastic left heart syndrome, enabling pediatric surgeons to avoid multiple open heart surgeries in children over the course of their pediatric years.

The business that was founded in 2012 is led by co-founder and CEO Doug Bernstien.